China Universal Asset Management Co., Ltd. Allogene Therapeutics, Inc. Transaction History
China Universal Asset Management Co., Ltd.
- $1.17 Billion
- Q3 2025
A detailed history of China Universal Asset Management Co., Ltd. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 38,892 shares of ALLO stock, worth $47,837. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,892
Previous 43,931
11.47%
Holding current value
$47,837
Previous $49,000
2.04%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ALLO
# of Institutions
185Shares Held
138MCall Options Held
76.6KPut Options Held
36.2K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$23 Million1.5% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$20.2 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il14MShares$17.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.02MShares$11.1 Million0.0% of portfolio
-
Primecap Management CO Pasadena, CA7.08MShares$8.71 Million0.01% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $177M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...